Royalty Pharma RPRX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Royalty Pharma's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Royalty Pharma's EPS (diluted)?
- Royalty Pharma (RPRX) reported EPS (diluted) of $0.67 in Q1 2026.
- How has Royalty Pharma's EPS (diluted) changed year-over-year?
- Royalty Pharma's EPS (diluted) increased by 21.8% year-over-year, from $0.55 to $0.67.
- What is the long-term trend for Royalty Pharma's EPS (diluted)?
- Over 3 years (2021 to 2025), Royalty Pharma's EPS (diluted) has grown at a 6.1% compound annual growth rate (CAGR), from $1.50 to $1.79.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.